相关实验视频
Updated: Sep 9, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.0K
从FAERS数据库中对与tirofiban相关的实际不良事件进行不成比例的分析
Qian Guo1, Xiang Li2, Chuanliang Zhao3
1Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Scientific reports
|September 1, 2025
概括
作为一种糖蛋白IIb/ IIIa受体阻断剂,蒂罗菲班在现实环境中会引起严重出血和其他不良反应. 这些副作用的监测,包括DIC等罕见的副作用,在给药后至关重要.
科学领域:
- 药物监督管理
- 心血管医学
- 神经学
背景情况:
- 蒂罗菲班是一种糖蛋白IIb/ IIIa受体对抗剂.
- 它主要用于急性冠状动脉综合征 (ACS) 和血管造形术 (PCI).
- 新出现的证据表明在缺血性中风 (IS) 内血管治疗中具有潜在的益处.
研究的目的:
- 评估Tirofiban的实际不良事件 (AE) 情况.
- 确定与Tirofiban使用相关的常见和罕见副作用.
- 为治疗Tirofiban的患者提供临床监测策略.
主要方法:
- 对FDA不良事件报告的不成比例分析 (2004年至今).
- 专注于Tirofiban是主要的嫌疑人.
- 对AE发作的时间分析.
主要成果:
- 已确认的已知副作用:出血 (例如内,胃肠道) 和血小板减少.
- 发现较少发生的出血事件:胸部出血,出血性休克.
- 检测到罕见但显著的副作用:急性呼吸衰竭,血液溶解,长时间的APTT,凝血病,扩散性血管内凝血 (DIC).
结论:
- 蒂罗菲班与多种出血和其他严重的副作用有关.
- 罕见的DIC和急性呼吸衰竭需要注意.
- 中位数的AE发病时间为1天,因此需要及时进行治疗后的监测,包括症状监测和实验室评估.
相关概念视频
Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Hazard Ratio
241
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
241
Relative Risk
340
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
340
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152

